SpectraCure AB (publ) (SPEC.ST)
SEK 3.59
(15.81%)
SEK 3.59
(15.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.35 Million SEK | 20.86% |
| 2022 | -26.97 Million SEK | -10.49% |
| 2021 | -24.41 Million SEK | -48.3% |
| 2020 | -16.46 Million SEK | -15.24% |
| 2019 | -14.28 Million SEK | -48.57% |
| 2018 | -9.61 Million SEK | -10.58% |
| 2017 | -8.69 Million SEK | -27.59% |
| 2016 | -6.81 Million SEK | -18.52% |
| 2015 | -5.75 Million SEK | -41.78% |
| 2014 | -4.05 Million SEK | 27.57% |
| 2013 | -5.59 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.03 Million SEK | 9.91% |
| 2024 Q1 | -6.29 Million SEK | 5.41% |
| 2023 FY | -24.02 Million SEK | 10.93% |
| 2023 Q1 | -5.33 Million SEK | 34.83% |
| 2023 Q3 | -4.37 Million SEK | 23.82% |
| 2023 Q2 | -5.74 Million SEK | -7.69% |
| 2023 Q4 | -6.65 Million SEK | -52.16% |
| 2022 Q1 | -6.23 Million SEK | -5.52% |
| 2022 Q3 | -5.59 Million SEK | 20.37% |
| 2022 Q4 | -8.18 Million SEK | -46.28% |
| 2022 FY | -26.97 Million SEK | -10.49% |
| 2022 Q2 | -7.02 Million SEK | -12.74% |
| 2021 Q4 | -5.9 Million SEK | -5.39% |
| 2021 Q3 | -5.6 Million SEK | 18.53% |
| 2021 Q2 | -6.87 Million SEK | -45.79% |
| 2021 Q1 | -4.71 Million SEK | -3.17% |
| 2021 FY | -24.41 Million SEK | -48.3% |
| 2020 Q2 | -4.73 Million SEK | -27.05% |
| 2020 Q4 | -4.57 Million SEK | -100.09% |
| 2020 FY | -16.46 Million SEK | -15.24% |
| 2020 Q1 | -3.72 Million SEK | -0.24% |
| 2020 Q3 | -2.28 Million SEK | 51.74% |
| 2019 FY | -14.28 Million SEK | -48.57% |
| 2019 Q4 | -3.71 Million SEK | -23.93% |
| 2019 Q3 | -3 Million SEK | 26.47% |
| 2019 Q2 | -4.08 Million SEK | -47.45% |
| 2019 Q1 | -2.76 Million SEK | 14.36% |
| 2018 Q4 | -3.23 Million SEK | -68.11% |
| 2018 Q1 | -18 Thousand SEK | 99.31% |
| 2018 Q2 | -4.44 Million SEK | -24600.0% |
| 2018 Q3 | -1.92 Million SEK | 56.77% |
| 2018 FY | -9.61 Million SEK | -10.58% |
| 2017 Q1 | -1.8 Million SEK | 2.73% |
| 2017 FY | -8.69 Million SEK | -27.59% |
| 2017 Q2 | -2.12 Million SEK | -17.67% |
| 2017 Q3 | -2.15 Million SEK | -1.43% |
| 2017 Q4 | -2.59 Million SEK | -20.38% |
| 2016 Q3 | -1.61 Million SEK | 19.6% |
| 2016 Q1 | -1.31 Million SEK | 29.75% |
| 2016 Q4 | -1.85 Million SEK | -15.3% |
| 2016 FY | -6.81 Million SEK | -18.52% |
| 2016 Q2 | -2 Million SEK | -53.15% |
| 2015 Q1 | -272.73 Thousand SEK | 83.52% |
| 2015 Q4 | -1.86 Million SEK | -46.14% |
| 2015 Q3 | -1.27 Million SEK | 45.4% |
| 2015 Q2 | -2.33 Million SEK | -756.94% |
| 2015 FY | -5.75 Million SEK | -41.78% |
| 2014 FY | -4.05 Million SEK | 27.57% |
| 2014 Q1 | -613.32 Thousand SEK | 0.0% |
| 2014 Q2 | -605.52 Thousand SEK | 1.27% |
| 2014 Q3 | -1.18 Million SEK | -95.31% |
| 2014 Q4 | -1.65 Million SEK | -39.92% |
| 2013 FY | -5.59 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 72.469% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 107.103% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 107.103% |
| Arcoma AB | 4.66 Million SEK | 558.176% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 83.817% |
| BICO Group AB (publ) | -618.3 Million SEK | 96.547% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 154.37% |
| CellaVision AB (publ) | 167.05 Million SEK | 112.781% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 67.617% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 27.799% |
| C-Rad AB (publ) | 44.24 Million SEK | 148.257% |
| Duearity AB (publ) | -25.76 Million SEK | 17.125% |
| Dignitana AB (publ) | -15.02 Million SEK | -42.094% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 77.478% |
| Getinge AB (publ) | 3.81 Billion SEK | 100.56% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 68.806% |
| Iconovo AB (publ) | -45.77 Million SEK | 53.358% |
| Integrum AB (publ) | 6.51 Million SEK | 427.855% |
| Luxbright AB (publ) | -25.8 Million SEK | 17.258% |
| Mentice AB (publ) | -679 Thousand SEK | -3044.477% |
| OssDsign AB (publ) | -91.95 Million SEK | 76.781% |
| Paxman AB (publ) | 12.61 Million SEK | 269.197% |
| Promimic AB (publ) | -9.11 Million SEK | -134.163% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 87.344% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 60.416% |
| ScandiDos AB (publ) | -13.48 Million SEK | -58.355% |
| Sectra AB (publ) | 518.49 Million SEK | 104.118% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 67.426% |
| Senzime AB (publ) | -133.74 Million SEK | 84.036% |
| Stille AB | 44.95 Million SEK | 147.497% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 99.405% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 155.449% |